CAMBRIDGE, MA, November 16, 2017 – Aurora BioPharma announces attendance at the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology taking place November 16 -19th at the Marriott Marquis in San Francisco.
The Society for Neuro-Oncology is a multidisciplinary organization formed 22 years to promote advances in neuro-oncology through research and education. The Society continues to grow and mature as the premier North American organization for clinicians, basic scientists, nurses and other health care professionals. The organization's main focus is central nervous system tumors in children and adults. The highlight of this year's meeting are the 10 Blue Ribbon Panel Recommendations related to the "Cancer Moonshot" program. A member of the Blue Ribbon Panel, Dr. WK Alfred Yung, will present an introduction to the Moonshot program and three prominent keynote speakers will offer presentations related to the specific recommendations.
Aurora is leading in the development of Chimeric Antigen Receptor (CAR) T therapy in solid tumors, with a diversified mid-stage clinical pipeline. Aurora's CAR T drug AU105 completed Phase I/IIa clinical trial in 16 Glioblastoma patients showing safety, tumor killing efficacy, double the median historic overall survival, with 3 patients alive after 5 years. Aurora's CAR T drug AU101 completed a Phase IIa trial in 6 Sarcoma patients, showing safety, tumor-killing and a Complete Response ---cancer free after 5 years. Aurora is planning a pivotal trial of its CAR T Cell therapy in Glioblastoma and Osteosarcoma.
This press release and any statements of representatives and partners of Aurora BioPharma, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors, many of which are beyond the Company's control. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Aurora BioPharma, Inc.
Tel: (617) 674-7718
Fax: (617) 674-7701
SOURCE Aurora BioPharma, Inc.